Evidence map›Paper›PMID 42499388›Full record

ArticleBlood neoplasia2026

Hypomethylating agents-venetoclax as salvage therapy for relapse of AML and MDS after allogeneic HCT.

Diana T Samuels, Brian J Ball, Ni-Chun Tsai, Salman Otoukesh, Shukaib Arslan, Hoda Pourhassan, Amanda Blackmon, Vaibhav Agrawal, Idoroenyi Amanam, Haris Ali and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Diana T SamuelsDepartment of Pharmacy, City of Hope National Medical Center, Duarte, CA.
Brian J BallDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Ni-Chun TsaiDivision of Biostatistics, Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA.
Salman OtoukeshDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Shukaib ArslanDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Hoda PourhassanDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Amanda BlackmonDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Vaibhav AgrawalDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Idoroenyi AmanamDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Haris AliDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Amandeep SalhotraDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Ibrahim AldossDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Paul KollerDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Ahmed AribiDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Karamjeet SandhuDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Andrew ArtzDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Eileen SmithDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Forrest StewartDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Pamela BeckerDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Monzr M Al MalkiDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Anthony SteinDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Guido MarcucciDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Stephen J FormanDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Ryotaro NakamuraDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Vinod PullarkatDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Relapse after allogeneic hematopoietic cell transplantation (alloHCT) remains a challenge for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and salvage therapy in this setting is not standardized. Given the efficacy of hypomethylating agents and venetoclax (HMA-VEN) in the frontline and relapsed settings, we evaluated the use of this therapy for post-alloHCT relapse. Eighty-three patients with AML (n = 69) or MDS (n = 14) who relapsed after alloHCT were included in this retrospective analysis. The median time to relapse after alloHCT was 7.0 months. Most patients (55%) had prior VEN exposure, and 28% of these patients had previously experienced treatment failure with a VEN-based regimen. HMA-VEN treatment-emergent toxicities were predominantly neutropenia and thrombocytopenia; however, the 30-day mortality was only 3.6%. There were 3 deaths within 30 days because of infectious complications. HMA-VEN led to a complete response (CR) or CR with incomplete hematological recovery in 48% of the patients, with 58% of these patients achieving minimal residual disease negativity. In multivariable analysis, European LeukemiaNet 2024 genetic risk stratification was a predictor of survival outcome. Additionally, prior VEN failure was not a predictor of overall survival. In conclusion, HMA-VEN provides an efficacious and well-tolerated option for post-alloHCT AML or MDS relapse regardless of their prior therapy and may allow responders to undergo a second alloHCT with curative intent.

Identifiers

PMID42499388
PMCPMC13396606

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.